Miranda Murray

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 492 citations

Treatment And Prevention, Medicine, Phase 2B +8

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

Deanna Kerrigan, Andrea Mantsios, Miguel Górgolas et al. · PLoS ONE · 2018 · 163 citations · Full text

Cost of refractory epilepsy in adults in the USA

Miranda Murray, Michael T. Halpern, Ilo E. Leppik · Epilepsy Research · 1996 · 112 citations

Health Economics, Refractory Epilepsy, Health Care Reimbursement +6

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

Miranda Murray, Antonio Antela, Anthony Mills et al. · AIDS and Behavior · 2020 · 76 citations · Full text

Patient-reported Outcomes, Week 48, Rilpivirine Over 48 +21

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

Miranda Murray, Martin Markowitz, Ian Frank et al. · HIV Clinical Trials · 2018 · 67 citations · Full text